Table 1 Baseline characteristics for patients with ankylosing spondylitis (2016)
Variable | Overall Population (N = 14,729) | Males (N = 7842) | Females (N = 6887) |
|---|---|---|---|
Mean Age (SD) | 50.00 (14.36) | 50.69 (14.62) | 49.21 (14.02) |
Age (Years) | |||
< 25 | 672 (4.6%) | 332 (4.2%) | 340 (4.9%) |
25–34 | 1530 (10.4%) | 843 (10.7%) | 687 (10.0%) |
35–44 | 2930 (19.9%) | 1482 (18.9%) | 1448 (21.0%) |
45–54 | 3806 (25.8%) | 1883 (24.0%) | 1923 (27.9%) |
55–64 | 3909 (26.5%) | 2160 (27.5%) | 1749 (25.4%) |
≥ 65 | 1882 (12.8%) | 1142 (14.6%) | 740 (10.7%) |
Insurance | |||
Commercial | 12,687 (86.1%) | 6605 (84.2%) | 6082 (88.3%) |
Medicare | 2149 (14.6%) | 1307 (16.7%) | 842 (12.2%) |
Geographic Region | |||
Northeast | 2423 (16.5%) | 1348 (17.2%) | 1075 (15.6%) |
North Central | 2953 (20.0%) | 1693 (21.6%) | 1260 (18.3%) |
South | 6400 (43.5%) | 3244 (41.4%) | 3156 (45.8%) |
West | 2895 (19.7%) | 1528 (19.5%) | 1367 (19.8%) |
Unknown | 58 (0.4%) | 29 (0.4%) | 29 (0.4%) |
Medication | |||
Biologics | 5795 (39.3%) | 3384 (43.2%) | 2411 (35.0%) |
Cox-2 inhibitor | 1154 (7.8%) | 569 (7.3%) | 585 (8.5%) |
Sulfasalazine | 1122 (7.6%) | 528 (6.7%) | 594 (8.6%) |
Methotrexate | 1591 (10.8%) | 695 (8.9%) | 896 (13.0%) |
Acetaminophen | 425 (2.9%) | 118 (1.5%) | 307 (4.5%) |
NSAIDs | 8065 (54.8%) | 3970 (50.6%) | 4095 (59.5%) |
Muscle Relaxants | 4273 (29.0%) | 1823 (23.2%) | 2450 (35.6%) |
Anticonvulsants | 2859 (19.4%) | 1110 (14.2%) | 1749 (25.4%) |
Opioids | 7980 (54.2%) | 3897 (49.7%) | 4083 (59.3%) |
Oral Glucocorticoids | 6928 (47.0%) | 3251 (41.5%) | 3677 (53.4%) |
Injectable Glucocorticoids | 4832 (32.8%) | 2115 (27.0%) | 2717 (39.5%) |